Skip to content

In-depth ECG Analysis for the Extraction of Biomarkers of Cardiac Mechanical Dispersion

In-depth ECG Analysis for the Extraction of Biomarkers of Cardiac Mechanical Dispersion

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06163911
Acronym
AFICIONADO
Enrollment
100
Registered
2023-12-11
Start date
2023-12-01
Completion date
2025-06-01
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Pathology

Brief summary

Left ventricular systolic dysfunction (LVSD) refers to impaired contraction of the left ventricle, and can lead to heart failure and death. Early identification of LVSD, which often remains asymptomatic for years, is therefore crucial to mitigate the associated risks through appropriate treatment. Echocardiographic screening of asymptomatic individuals is costly, requires access to experts, and the criteria for selecting potential high-risk individuals for screening remain unclear. Unlike echocardiography, the electrocardiogram (ECG) is a relatively low-cost procedure, routinely available and requiring little technical training to set up the examination and collect data, making it an interesting tool for early detection of LVSD.

Interventions

DEVICEECG

Routine care 12-lead electrocardiogram

DEVICEEchocardiography

Routine care echocardiography

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum

Inclusion criteria

* Person who has received full information on the organization of the research and has not objected to the use of this data; * Age ≥ 50; * Persons who have undergone an echocardiographic examination and a 12-lead ECG examination during consultations at the CHRU de Nancy; * Persons with at least one cardiovascular risk (obesity, diabetes, hypertension, etc.).

Exclusion criteria

* People with a history of heart disease (ischemic, valvular); * Patients with significant 12-lead ECG abnormalities (complete bundle branch block, sequelae of myocardial infarction, etc.); * ECG tracings or echocardiograms that cannot be analyzed.

Design outcomes

Primary

MeasureTime frame
F1 score for classification of cardiac contractility abnormalities12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026